Cyclerion Therapeutics to Participate in Jefferies Virtual Healthcare Conference

CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced that Company management will present a corporate overview at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 4:00 p.m. ET. Management will also be available for one-on-one meetings and investors may request a meeting through Jefferies.

The live webcast can be accessed via the Investors & Media section of the Cyclerion website at https://ir.cyclerion.com/news-events/event-calendar. An archived replay of the event will be available on the site for approximately 90 days following the presentation.

About Cyclerion Therapeutics 

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function. Cyclerion’ is advancing novel, first-in-class, CNS-penetrant, sGC stimulators that modulate a key node in a fundamental CNS signaling pathway. The multidimensional pharmacology elicited by the stimulation of sGC has the potential to impact a broad range of CNS diseases. The most advanced compound, CY6463 has shown rapid improvement in biomarkers associated with cognitive function and is currently in clinical development for Alzheimer's Disease with Vascular pathology (ADv) and Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS) and Cognitive Impairment Associated with Schizophrenia (CIAS). Cyclerion is also advancing CY3018, a next generation sGC stimulator.

For more information about Cyclerion, please visit https://www.cyclerion.com/ and follow us on Twitter (@Cyclerion) and LinkedIn (www.linkedin.com/company/cyclerion).

InvestorsCarlo Tanzi, Ph.D.Kendall Investor Relations[email protected]

MediaAmanda SellersVerge Scientific Communications[email protected]

Source: Cyclerion Therapeutics, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Singularity Future Technology Ltd. Announces Pricing of $5.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
• WellSpan and Johns Hopkins Medicine extend oncology collaboration, expanding access to world-class cancer care across Central Pennsylvania
• JSC ‘Siguldas ciltslietu un mākslīgās apsēklošanas stacija‘ unaudited interim report for the first six months of 2026